CSV April 5, 2023 through April 5, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VISUAL	2. BACKGROU	*First*	8099	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second*	Line 6 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INSPECTION OF INJECTIONS	ND/*2.2 Patient Risk*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	paragraph 3: Change 109 particles/kg to: 10^9 particles/kg
FLUVOXAMINE MALEATE	ASSAY/ *Procedure*	*Second Supplement to USP40–NF35*	8797	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2of *Solution A*: Change 1 g/L to: 1.1 g/L
ALMOTRIPTAN MALATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Interim Revision Announcement (Official May 01, 2017)*	Online	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide. $C_{17}H_{25}N_3O_3S$ 351.46 to: 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide hydrochloride. C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CILOSTAZOL	*USP Reference standards <11>*	*USP40–NF35*	3418	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	$_{17}H_{25}N_3O_3S \cdot HCl$ 387.92 Line 2 of USP Cilostazol Related Compound C RS: Change 1-(4-(5-Cyclohexyl-1*H*-tetrazol-1-yl)butyl)-6-(4-(1-cyclohexyl-1*H*-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1*H*)-one. $C_{31}H_{43}N_9O_3$ 589.73 to: 1-(4-(1-Cyclohexyl-1*H*-tetrazol-5-yl)butyl)-6-(4-(1-cyclohexyl-1*H*-tetrazol-5-yl)butoxy)-3,4-dihydroquinoli

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								n-2(1*H*)-one. $C_{31}H_{45}N_9O_2$ 575.75
HYDROXYZINE HYDROCHLORIDE TABLETS	ASSAY/ *Procedure*	*USP40–NF35*	4542	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2of *Solution B*: Change (0.5: 99.5) to: (0.05: 99.95)
VERAPAMIL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP40–NF35*	6680	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Row 5 of column 2 of *Table 9*: Change 4 to: 5
ALMOTRIPTAN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP40–NF35*	8708	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 4 of USP Almotriptan Related Compound B RS: Change $C_{15}H_{22}N_3O_2S$ to: $C_{15}H_{21}N_3O_2S$ AND Line 2 of USP Almotriptan Related Compound D RS: Change 1-[({3-[2-(Dimet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide. $C_{17}H_{25}N_3O_3S$ 351.46 to: 1-[({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine *N*-oxide hydrochloride. $C_{17}H_{25}N_3O_3S \cdot HCl$ 387.92
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	7. PERSONAL PROTECTIVE EQUIPMENT	*First Supplement to USP40–NF35*	Online	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of paragraph 2: Change antineoplastic HDs. to: injectable antineoplastic HDs.
CHLOROQUINE PHOSPHATE	IMPURITIES/*Organic Impurities*	*USP40–NF35*	3377	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *Analysis*: Change Calculate the percentage of each specified impurity

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Calculate the percentage of each specified impurity, other than chloroquine related compound G, AND In *Analysis*/second equation/variable definition list: Change r_U=peak response of chloroquine *N*-oxide or any other impurity from the *Sample solution* r_U=peak response of chloroquine related compound G or any other impurity from the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GLUTARAL CONCENTRATE	ASSAY/ *Procedure*	*USP40–NF35*	4414	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 7 of *Analysis*: Change Add a weighed quantity of Concentrate containing 1.2 g of glutaral by means of a suitable weighing pipet. to: Add 1.2 g of Glutaral Concentrate.
MYCOPHENOLIC ACID DELAYED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5257	17-Nov-2017	1-Dec-2017	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Mobile phase*, *Standard solution*, *Sample solution*, and *Chromatographic system*: to: *Mobile phase*, *Diluent*, *Standard solution*, *Sample solution*, and *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Assay*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*c system*: Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Chromatographi c system* (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatography <*621*>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicate injections determined from the peak response ratios is not more than 2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatograph, record the chromatograms, and measure the responses for the major peaks.
MYCOPHENOLATE MOFETIL FOR ORAL SUSPENSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5251	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED ASHWAGANDHA ROOT EXTRACT	COMPOSITION /*Content of Withanolides*	*USP40–NF35*	6804	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Add *Solution B*: Acetonitrile, filtered and degassed
EFAVIRENZ	SPECIFIC TESTS/ *Enantiomeric Purity*	*Second Supplement to USP40–NF35*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Mobile phase*: Change Hexane and ethanol (97:3) to: Hexane and absolute alcohol (97:3)
REAGENTS, INDICATORS AND SOLUTIONS	SOLUTIONS/*Volumetric Solutions*/*1 N Sulfuric Acid VS*	*USP40–NF35*	2434	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 3 of *Standardization*: Change dried at 150° to: dried at 105°
GADOTERIDOL	*Chromatographic purity*/*Test 2 (Nongadolinium-Containing Impurities)*	*USP40–NF35*	4360	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *pH 5.0 Buffer*: Change *50 mM Ammonium* to: *50 mM Ammonium phosphate buffer* AND Line 1 of *pH 7.0 Buffer*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								50 mM Ammonium to: *50 mM Ammonium phosphate buffer*
MEMANTINE HYDROCHLORIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP40–NF35*	5000	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change C_S = concentration of USP Memantine Hydrochloride RS in the *Standard solution* (µg/mL) to: C_S = concentration of USP Memantine Hydrochloride RS in the *Standard stock solution* (mg/mL)
PEMETREXED DISODIUM	IMPURITIES/*Organic*	*USP40–NF35*	5588	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote b: Change {4-[2-(2-Amino-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities/Table 2							1-methyl-4-oxo-4, 7-di hydro-1*H* -pyr rolo[2,3 -*d*]pyrimidin-5-yl)e thyl]benzoyl}-4- L-glutamyl-L- glutamic acid. to: {4?[2?(2?Amino ?4?oxo?4,7?dih ydro?1*H* ?p yrrolo [2,3?*d*]pyrimidin?5?yl) ethyl]benzoyl}?4 ?L?glutamyl?L? glutamic acid.
FLUVOXAMINE MALEATE	CHEMICAL INFORMATION	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 4:Change 5-Methoxy-4’-(t rifluoromethyl)v alerophenone (*E*)-*O* -(2-aminoethyl) oxime, maleate (1:1) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(*E*)-5-Methoxy-4’-(trifluoromethyl) valerophenone *O*-(2-aminoethyl) oxime, maleate (1:1)
ENOXAPARIN SODIUM INJECTION	SPECIFIC TESTS/*Anti-Factor IIa Activity*	*USP40–NF35*	3982	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Delete *Standard solutions*: Dilute USP Enoxaparin Sodium Solution for Bioassays RS with *pH 7.4 buffer* to obtain four dilutions having concentrations in the range between 0.015 and 0.075 IU of Anti-Factor IIa activity/mL.
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Dissolution <711>/Test 2*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change *Buffer solution* and *Mobile phase*—Prepare as directed in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution* and *Mobile phase*—Prepare as directed in the *Assay*. AND Line 1 of *Chromatographic system*: Change (see *Chromatography* *<621>*)—Proceed as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: (see *Chromatography* *<621>*)—Proceed as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed in the *Assay*.
MYCOPHENOLATE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuran-1-one.
MONOBASIC POTASSIUM PHOSPHATE	IMPURITIES/*Arsenic, Method I <211>*	*USP40–NF35*	7847	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change 3 µg/g to: NMT 3 µg/g
POTASSIUM	ASSAY/	*Revision*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CITRATE EXTENDED-RELEASE TABLETS	*Procedure*	*Bulletin (Official April 01, 2017)*					*Supplement to USP41–NF36*	*Chromatographic system*/*Column*: Change 10-µm to: 5-µm AND In the variable definition list in *Analysis*: Change r_U = citrate peak area from the *Sample solution* r_S = citrate peak area from the *Standard solution* to: r_U = citric acid peak area from the *Sample solution* r_S = citric acid peak area from the *Standard solution* AND Change *M*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_2= molecular weight of citrate ($C_6H_5O_7$), 189.10 to: M_{r2} = molecular weight of citric acid ($C_6H_8O_7$), 192.13
CALCIPOTRIENE OINTMENT	IMPURITIES/*Organic Impurities*	*USP40–NF35*	3114	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote a of *Table 1*: Change (5*Z*,7*Z*,22*E*,24*R*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol. to: (5*Z*,7*Z*,22*E*,24*S*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol.
ISOSORBIDE DINITRATE EXTENDED-RELEASE	*Assay*	*USP40–NF35*	4708	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								*standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature,dilute with water to 1000 mL, mix, degas,and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution* —Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Chromatographi c system* (see *Chromatograph y <621>*)—The liquid chromatograph

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								response ratios is not more than 2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the responses for the major peaks.
MYCOPHENOLATE MOFETIL FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5250	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
PEMETREXED FOR INJECTION	ASSAY/*Procedure/Analysis*	*USP40–NF35*	5590	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change *M*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_2= molecular weight of pemetrexed disodium, 597.49 to: M_{r2} = molecular weight of pemetrexed disodium (anhydrous), 473.37
FLUVOXAMINE MALEATE	IMPURITIES/*Organic Impurities*/*Table 1*	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote b:Change 5-Methoxy-1-[4-(trifluoromethyl) phenyl]-1-pentanone (*E*)-*O*-[2-[(2-succinyl) amino]ethyl]oxime. to: (*E*)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone *O*-[2-[(2-succinyl) amino]ethyl]oxime.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Footnotes c– g: Delete the space before oxime
REAGENTS	REAGENT SPE *Brom elain/Activity Determination*	*USP40–NF35*	2339	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Buffer solution*: Change Add 150 mg of sodium chloride to: Add 150 g of sodium chloride
FENOLDOPAM MESYLATE	*USP Reference standards <11>*	*USP40–NF35*	4159	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Fenoldopam Related Compound A RS: Change 1-Methyl-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt). $C_{17}H_{18}ClNO_3 \cdot CH_4SO_3$ 415.89 to: 6-Chloro-1-(4-hydroxyphenyl)-3-methyl-2,3,4,5-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								tetr ahydro -1*H* -benzo[*d*]azepine-7,8-dio l hydrochloride (*N* -Methyl-6-chloro -2,3,4,5-tetrahy dro-1-(4-hydrox yphe nyl)-1*H* -3-benzazepine- 7,8-diol hydrochloride). $C_{17}H_{19}ClNO_3$ · HCl 356.24
MEBENDAZOL E	IM PUR ITIES/*Organic Impurities*/*Table 2*	*USP40–NF35*	4968	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change footnotes [d]Ethyl 5-benzoyl -1-methylbenzi midazol-2-ylcar bamate. [e]Methyl 5-(4-tol uoyl)-1-methylb enzimidazol-2-yl carbamate. to: [d]Ethyl (5- benzo

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl-1*H*-benzimidazol-2-yl)carbamate. [e]Methyl 5-(4-toluoyl)-1*H*-benzimidazol-2-ylcarbamate.
MYCOPHENOLATE SODIUM	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Footnote a of *Table 2*: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CANDESARTAN CILEXETIL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP40–NF35*	8730	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	1-one. Line 2 of USP Candesartan Cilexetil Related Compound D RS: Change 1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl *H* -tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1*H* -benzimidazole-4-carboxylate. to: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl *H* -tetrazol-5-yl)-[1,1'-biphenyl]-4-yl}methyl)-2-oxo-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2, 3-di hydro-1*H* -benzimidazole-4-carboxylate.
ENALAPRIL MALEATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Table 1*	*USP40–NF35*	3971	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Row 3 of Column 3: Change 100 to: 200
ONDANSETRON INJECTION	*USP Reference standards <11>*	*USP40–NF35*	5443	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H* -carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H* -carbazol-4-one hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROCURONIUM BROMIDE	IMPURITIES/*Limit of 2-Propanol/Analysis*	*USP40–NF35*	6066	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of the variable definition list: Change r_U = peak response of any impurity from the *Sample solution* r_S = peak response of rocuronium bromide from the *Dilute standard solution* to: r_U = peak response of 2-propanol from the *Sample solution* r_S = peak response of 2-propanol from the *Dilute standard solution*
OIL- AND WATER-SOLUBLE VITAMINS	STRENGTH	*USP40–NF35*	7290	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CAPSULES								*1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione/Sample solution*:Change in the directions for the *Sample solution* to: in the directions for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample stock solution*
MONOSACCHARIDE ANALYSIS	PROCEDURES/*Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids*	*First Supplement to USP40–NF35*	8059	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 6 of *Analysis*: Change (1 M = 1nmol/mL). to: (1 µM = 1nmol/mL).
LEVOTHYROXINE SODIUM TABLETS	IMPURITIES/*Limit of Liothyronine Sodium*	*First Supplement to USP40–NF35*	8328	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 4 of *Analysis*: Change Calculate the percentage of levothyroxine sodium ($C_{15}H_{11}I_3NNaO_4$) to: Calculate the percentage of liothyronine sodium ($C_{15}H_{11}I_3NNaO_4$)
DOXAZOSIN MESYLATE	ASSAY/*Procedure*/*System suitability*/*Suitability*	*USP40–NF35*	3874	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Resolution*: Change NLT 4 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	requirements							NLT 2
PERPHENAZINE	IMPURITIES/*Organic Impurities/ Chromatographic system*	*USP40–NF35*	5649	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Column*: Change 4.6-mm to: 4.0-mm
OIL-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USP40–NF35*	7265	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 21 of *Sample solution*: Change Further dilute this solution to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Vitamin D/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Vitamin E*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione (Vitamin K_1)*:Change as directed for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Beta Carotene*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7375	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Vitamin E, Method 1/Sample solution: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1/Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution*
ACETAMINOPHEN AND CODEINE	PERFORMANCE TESTS	*First Supplement to USP40–NF35*	8202	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Dissolution <711>/*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHOSPHATE TABLETS								*Analysis*:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the second Calculate statement in *Uniformity of Dosage Units <905>/ Procedure for content unifor mity/Analysis*: Change Calculate the quantity, in mg/mL, of the labeled amount of codeine phosphate to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TIMOLOL MALEATE	MULTIPLE SECTIONS	*Second Supplement to USP40–NF35*	Online	28-Jul-2017	1-Aug-2017	*USP41–NF36*	*USP41–NF36*	Calculate the quantity, in mg, of codeine phosphate The version of the Timolol Maleate monograph which appeared in the *Second Supplement to USP 40–NF 35* did not include the revisions approved in the version appearing in the *First Supplement to USP 40–NF 35*. The version appearing in the *First Supplement* should be used. The file as it should have appeared in the *Second Supplement* is attached to the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compendial notice found at http://www.uspnf.com/notices/second-supplement-usp-40-nf-35-online-timolol-maleate.
ONDANSETRON ORAL SOLUTION	*USP Reference standards <11>*	*USP40–NF35*	5444	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
OIL-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7248	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1/Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Phytonadione/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL- AND WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP40–NF35*	7318	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*Sample stock solution* Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D),*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Method 1/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1/*Sample solution*: Change retained as specified in the directions for the *Sample solution* to: retained as specified in the directions for the *Sample stock solution*

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- …
- Next page Next ›

- Last page Last »